However, the absence of existing inhibitors of both ALKBH3 and NHEJ1 undermines their importance as a therapeutic strategy to prevent or minimize the chance of ALL disease relapse after complete remission. This evidence concerns the gene ALKBH3 and acute lymphoblastic leukemia.